Study questions the validity of new LDL cholesterol targets


  • Dawn O'Shea
  • Univadis Medical News
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

The negative results of numerous trials call into question the validity of using low density lipoprotein (LDL) cholesterol as a surrogate target for the prevention of cardiovascular disease (CVD), say the authors of a review of published evidence.

The systematic review included randomised controlled trials (RCTs) of cholesterol reduction with a statin, ezetimibe, or a PCSK9 inhibitor. LDL-C reduction targets were ≥30 per cent for moderate-risk and ≥50 per cent for high-risk individuals.

The majority of studies were of “excellent quality and had a low overall risk of bias”.

Of 13 RCTs that met the target, only one reported a mortality benefit and five reported a reduction in CVD events. Of 22 that did not meet the target, four reported a mortality benefit and 14 reported a reduction in CVD events.

A beneficial reduction in cardiovascular events was seen with reductions as little as 11-15 per cent, while a lack of cardiovascular benefit was seen with reductions of ≥50 per cent.

“This analysis highlights the discordance between a well-researched clinical guideline written by experts and empirical evidence gleaned from dozens of clinical trials of cholesterol reduction,” say the authors.

The review has a number of limitations that must be considered when interpreting the results.